P/E ratio for Intra-Cellular Therapies (ITCI)
P/E ratio as of April 2024 (TTM): -44.8
According to Intra-Cellular Therapies's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -44.8012. At the end of 2022 the company had a P/E ratio of -19.5.
P/E ratio history for Intra-Cellular Therapies from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -19.5 | 30.1% |
| 2021 | -15.0 | 52.36% |
| 2020 | -9.81 | -23.34% |
| 2019 | -12.8 | 219.21% |
| 2018 | -4.01 | -41.28% |
| 2017 | -6.83 | 21.76% |
| 2016 | -5.61 | -69.65% |
| 2015 | -18.5 | 11.01% |
| 2014 | -16.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | -8.99 | -79.94% | 🇺🇸 USA |
 MediciNova MNOV | -5.28 | -88.21% | 🇺🇸 USA |
 Curis CRIS | -1.45 | -96.76% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.